Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
News
News and Insights from Our Multidisciplinary Team of Experts
Flagship Spotlight: Adam Beharry
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
White Paper: Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
Flagship Biosciences Expands Tissue Image Analysis Capabilities at New Colorado Location in Support of Pharmaceutical and Clinical Clients
Broomfield, CO – June 1, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company has moved its headquarters to a new location in Broomfield, Colorado, just north of Denver. The office, at 11800 Ridge...
Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment
Cambridge, MA and Westminster, CO — May 12, 2021 — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today...
Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist InterpretationCambridge, MA and Westminster, CO – April 12, 2021 — Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
PUBLICATIONS/POSTERS
Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation (Poster No. 433 #AACR2021 in partnership with Leap Therapeutics)
Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study, we demonstrate an approach for clinically validating a RNAscope chromogenic in-situ hybridization...
A Novel Image Analysis Assay for Determining Programmed Death-Ligand (PD-L1 [22C3]) in Non-small Cell Lung Cancer that Accounts for Tissue and Alveolar Macrophages (Poster No. 435 #AACR2021)
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to the check point inhibitor drug pembrolizumab. However, interpretation of the PD-L1 (22C3) immunohistochemistry...
Characterizing the Heterogeneity of CD8 Inflammation in Biopsied Tumor Tissues Using Novel Image Analysis Techniques (Poster No. 3137 #AACR2021 in partnership with Scholar Rock)
Key takeaways An image analysis-based algorithm was used to assess CD8 expression in numerous tumor nests in non-small cell lung cancer, bladder, and melanoma tumor samples Measuring CD8 expression within tumor nests rather than averaging across a whole tissue section...
EVENTS
Oncology Companion Diagnostics Xchange West Coast
Join Flagship for the Oncology Companion Diagnostics Xchange at hubXchange West. February 6-9, 2023. Attending hubXchange West? Meet with us to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program....
Spatial Biology for Immuno-Oncology Summit 2023
Visit Flagship at the SB-IO Summit.January 17-19, 2023. Attending the inaugural SB-IO Summit? Stop by our booth to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program. AI-powered digital pathology solutions...
ASH 2022
Visit Flagship at ASH | Booth #1015. December 10-13, 2022. Attending ASH 2022? Stop by our booth to discuss how we can partner with you for end-to-end biomarker support. Discover our recently expanded services menu and pick up a map of our favorite New Orleans...